Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 8
Submit an article Journal homepage
35
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable

Albert Picado Barcelona Centre for International Health Research (CRESIB, Hospital Clínic, Universitat de Barcelona), Roselló 132, 4th Floor,Barcelona 08036, Spain. [email protected]
,
Suman Rijal B.P. Koirala Institute of Health Sciences, Dharan, Nepal
,
Shyam Sundar Banaras Hindu University (BHU), Institute of Medical Sciences, Varanasi, Uttar Pradesh 221005, India
&
Marleen Boelaert Institute of Tropical Medicine, Nationalestraat 155, Antwerpen B-2000, Belgium
Pages 839-841 | Published online: 10 Jan 2014

References

  • Alvar J, Vélez ID, Bern C et al. The WHO Leishmaniasis control team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7(5), e35671 (2012).
  • Chowdhury R, Huda MM, Kumar V et al. The Indian and Nepalese programmes of indoor residual spraying for the elimination of visceral leishmaniasis: performance and effectiveness. Ann. Trop. Med. Parasitol. 105(1), 31–35 (2011).
  • Picado A, Singh SP, Rijal S et al. Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ 341, c6760 (2010).
  • Boelaert M, Meheus F, Sanchez A et al. Thepoorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop. Med. Int. Health 14(6), 639–644 (2009).
  • Adhikari SR, Maskay NM, Sharma BP. Paying for hospital-based care of kala-azar in Nepal: assessing catastrophic, impoverishment and economic consequences. Health Policy Plan. 24(2), 129–139 (2009).
  • Singh S, Kumar J, Singh R, Dwivedi SN. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study. Int. Soc. Infect. Dis. 4(4), 203–208 (2000).
  • Sharma BP, Maskay NM, Adhikari SR et al. Socio-economic determinants of kala-azar in Nepal. J. Nepal Health Res. Council 2(1), 35–42 (2004).
  • Shah H. Prevalence of visceral leishmaniasis associated with the behaviors of the people in rural areas. J. Nepal Med. Assoc. 44(160), 116–120 (2005).
  • Thakur CP. Kala-azar may break out in epidemic form. The Times Of India, 27th April, (2005).
  • Hasker E, Singh SP, Malaviya P et al. Factors associated with visceral leishmaniasis in rural Bihar, India; a multilevel analysis. Trop. Med. Int. Health (Suppl. 2), 55–62 (2010).
  • Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 22(12), 552–557 (2006).
  • Pascual Martínez F, Picado A, Roddy P, Palma P. Low castes have poor access to visceral leishmaniasis treatment in Bihar, India. Trop. Med. Int. Health doi:10.1111/j.1365-3156.2012.02960.x (2012) (Epub ahead of print).
  • Chappuis F, Rijal S, Soto A, Menten J, Boelaert M. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 333(7571), 723 (2006).
  • World Health Organization. Control of the leishmaniases. World Health Organ. Tech. Rep. Ser. (949), xii–xiii, 1–186, back cover (2010).
  • den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. Clin. Microbiol. Infect. 17(10), 1471–1477 (2011).
  • Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med. 362(6), 504–512 (2010).
  • Sundar S, Sinha PK, Rai M et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 377(9764), 477–486 (2011).
  • van Griensven J, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet 377(9764), 443–444 (2011).
  • Matlashewski G, Arana B, Kroeger A et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect. Dis. 11(4), 322–325 (2011).
  • Sinha PK, Roddy P, Palma PP et al. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am. J. Trop. Med. Hyg. 83(2), 357–364 (2010).
  • Sundar S, Singh A, Rai M et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis after a decade of use in India. Clin. Infect. Dis. doi:10.1093/cid/cis474 (2012) (Epub ahead of print).
  • Hasker E, Singh SP, Malaviya P et al. Factors Associated with Visceral Leishmaniasis in Rural Bihar, India. Emerg. Infect. Dis. (2012) (In Press).
  • John TJ, Dandona L, Sharma VP, Kakkar M. Continuing challenge of infectious diseases in India. Lancet 377(9761), 252–269 (2011).
  • Singh SP, Hasker E, Picado A et al. Risk factors for visceral leishmaniasis in India: further evidence on the role of domestic animals. Trop. Med. Int. Health 15(Suppl. 2), 29–35 (2010).
  • Killick-Kendrick R. Education is key to controlling visceral leishmaniasis. Bull. WorldHealth Organ. 88(1), 11–12 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.